Elyse Stock

4.0k total citations · 3 hit papers
44 papers, 3.0k citations indexed

About

Elyse Stock is a scholar working on Psychiatry and Mental health, Sensory Systems and Clinical Psychology. According to data from OpenAlex, Elyse Stock has authored 44 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Psychiatry and Mental health, 7 papers in Sensory Systems and 6 papers in Clinical Psychology. Recurrent topics in Elyse Stock's work include Schizophrenia research and treatment (22 papers), Migraine and Headache Studies (16 papers) and Bipolar Disorder and Treatment (10 papers). Elyse Stock is often cited by papers focused on Schizophrenia research and treatment (22 papers), Migraine and Headache Studies (16 papers) and Bipolar Disorder and Treatment (10 papers). Elyse Stock collaborates with scholars based in United States, Japan and Germany. Elyse Stock's co-authors include William H. Carson, Anutosh Ranjan Saha, Robert D. McQuade, Ronald N. Marcus, Vladimir Coric, Mirza W. Ali, Stephen R. Marder, Г. Ингенито, Taro Iwamoto and Robert Croop and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Elyse Stock

42 papers receiving 2.9k citations

Hit Papers

Efficacy, safety, and tolerability of rimegepant orally d... 2019 2026 2021 2023 2019 2019 2020 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
    2019 276 citations Robert Croop, Peter J. Goadsby et al. The Lancet profile →
  2. Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine
    2019 265 citations Richard B. Lipton, Robert Croop et al. profile →
  3. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial
    2020 233 citations Robert Croop, Richard B. Lipton et al. The Lancet profile →

Peers

Elyse Stock
Comparison fields: 5 of 103
  • Psychiatry and Mental health 2.5k
  • Pathology and Forensic Medicine 471
  • Physiology 467
  • Clinical Psychology 387
  • Pharmacology 334
Replace Virginia L. Stauffer with:
Virginia L. Stauffer United States
J. Craig Nelson United States
Holland C. Detke United States
Paul Yeung United States
Ronald N. Marcus United States
James M. Martinez United States
Sameer Jauhar United Kingdom
Kenneth W. Sommerville United States
Martina Hummer Austria
Chiao‐Chicy Chen Taiwan
Virginia L. Stauffer United States View profile →
Citations per field, relative to Elyse Stock
Elyse Stock · 1×
Citations per year, relative to Elyse Stock
Elyse Stock · 1×

Countries citing papers authored by Elyse Stock

Since Specialization
Citations

This map shows the geographic impact of Elyse Stock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elyse Stock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elyse Stock more than expected).

Fields of papers citing papers by Elyse Stock

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elyse Stock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elyse Stock. The network helps show where Elyse Stock may publish in the future.

Co-authorship network of co-authors of Elyse Stock

This figure shows the co-authorship network connecting the top 25 collaborators of Elyse Stock. A scholar is included among the top collaborators of Elyse Stock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elyse Stock. Elyse Stock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Rimegepant is Safe and Tolerable for the Acute Treatment of Migraine in Patients Using Preventive Migraine Medications: Results from a Long-Term Open-Label Safety Study (2370)
2021 ·Neurology ·Jack Schim, Susan Hutchinson, Richard B. Lipton, Robert Croop, Elyse Stock, Alexandra Thiry, Charles M. Conway, Meghan Lovegren, Vlad Coric, (unknown)
4
2
Low Rates of Rescue Medication Usage in Subjects Treated with a Single Dose of Rimegepant 75 mg for the Acute Treatment of Migraine: Results from 3 Phase 3 Clinical Trials (2342)
2021 ·Neurology ·Timothy R. Smith, Peter McAllister, Gary Berman, David Kudrow, Richard B. Lipton, (unknown), Alexandra Thiry, Elyse Stock, (unknown), Beth Morris, Vlad Coric, Robert Croop
2
3
Rimegepant is Effective for the Acute Treatment of Migraine in Subjects Taking Concurrent Preventive Medication: Results From 3 Phase 3 Trials (2091)
2020 ·Neurology ·Jelena Pavlović, David W. Dodick, Lawrence C. Newman, Richard B. Lipton, Elyse Stock, Alexandra Thiry, Charles M. Conway, (unknown), Beth Morris, Vladimir Coric, Robert Croop
1
4
Rimegepant 75 mg Demonstrates Safety and Tolerability Similar to Placebo With No Effects of Age, Sex, or Race in 3 Phase 3 Trials (1609)
2020 ·Neurology ·Jack Schim, Susan Hutchinson, Richard B. Lipton, Elyse Stock, Alexandra Thiry, Charles M. Conway, (unknown), Beth Morris, Vladimir Coric, Robert Croop
1
5
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial breakdown →
2020 ·The Lancet ·Robert Croop, Richard B. Lipton, David Kudrow, David Stock, Lisa Kamen, Charles M. Conway, Elyse Stock, Vladimir Coric, Peter J. Goadsby
233
6
Acute Treatment of Migraine with Oral Rimegepant 75 mg Confers Robust Improvement in Absenteeism, Presenteeism and Productivity: Results from a One Year, Open-Label, Safety Study (BHV3000-201) (1864)
2020 ·Neurology ·Gilbert L’Italien, Robert Croop, Elyse Stock, Alexandra Thiry, (unknown), Meghan Lovegren, (unknown), Vladimir Coric, Richard B. Lipton
1
7
Long-Term Safety of Rimegepant 75 mg for the Acute Treatment of Migraine (Study 201) (4829)
2020 ·Neurology ·Robert Croop, Gary Berman, David Kudrow, Kathleen Mullin, Elyse Stock, Alexandra Thiry, Charles M. Conway, (unknown), Meghan Lovegren, Vladimir Coric, Richard B. Lipton
10
8
Rimegepant 75 mg Demonstrates Superiority to Placebo on Nausea Freedom: Results from a Post Hoc Pooled Analysis of 3 Phase 3 Trials in the Acute Treatment of Migraine (2402)
2020 ·Neurology ·Peter McAllister, Gary Berman, David Kudrow, Timothy R. Smith, Richard B. Lipton, Elyse Stock, David Stock, Charles M. Conway, (unknown), Beth Morris, Vladimir Coric, Robert Croop
1
9
Patient Preference and Improved Clinical Global Impression of Change with Rimegepant for the Acute Treatment of Migraine: Results from a Long-Term Open-Label Safety Study (Study 201) (2112)
2020 ·Neurology ·(unknown), Robert Croop, Richard B. Lipton, Elyse Stock, Alexandra Thiry, Charles M. Conway, Meghan Lovegren, Vladimir Coric, Gilbert L’Italien
0
10
Rimegepant is Effective for the Acute Treatment of Migraine in Patients Who Have Discontinued or Currently Use Triptans: Results from 3 Phase 3 Clinical Trials (2114)
2020 ·Neurology ·Robert Croop, (unknown), Alexandra Thiry, Elyse Stock, Charles M. Conway, Beth Morris, Vladimir Coric, Richard B. Lipton
0
11
Rimegepant 75 mg is Effective for the Acute Treatment of Migraine Regardless of Attack Frequency: Results From 3 Phase 3 Trials (1212)
2020 ·Neurology ·Morris Levin, Dawn C. Buse, Andrew Blumenfeld, Richard B. Lipton, Elyse Stock, Alexandra Thiry, (unknown), (unknown), Beth Morris, Vladimir Coric, Robert Croop
2
12
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial breakdown →
2019 ·The Lancet ·Robert Croop, Peter J. Goadsby, David Stock, Charles M. Conway, Micaela Forshaw, Elyse Stock, Vladimir Coric, Richard B. Lipton
276
13
Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder
2010 ·Depression and Anxiety ·Vladimir Coric, Howard Feldman, Dan A. Oren, Anantha Shekhar, Joseph Pultz, Randy Dockens, Xiaoling Wu, (unknown), Shu-Pang Huang, (unknown), Terrye Delmonte, (unknown), Daniel L. Zimbroff, Jack A. Grebb, Andrew W. Goddard, Elyse Stock
136
14
Management of Acute Agitation in Patients With Bipolar Disorder
2007 ·Journal of Clinical Psychopharmacology ·Dan Zimbroff, Ronald N. Marcus, George Manos, Elyse Stock, Robert D. McQuade, Philippe Auby, Dan A. Oren
70
15
Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol
2006 ·Psychopharmacology ·(unknown), Richard C. Josiassen, Ronald N. Marcus, Dan A. Oren, George Manos, Elyse Stock, William H. Carson, Taro Iwamoto
80
16
Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study
2006 ·Current Medical Research and Opinion ·(unknown), Ronald N. Marcus, Dan A. Oren, George Manos, Elyse Stock, William H. Carson, Robert D. McQuade
29
17
Effectiveness of aripiprazole v. Haloperidol in acute bipolar mania
2005 ·The British Journal of Psychiatry ·Eduard Vieta, Michel Bourin, Raymond Sanchez, Ronald N. Marcus, Elyse Stock, Robert D. McQuade, William H. Carson, (unknown), René Swanink, Taro Iwamoto
137
18
P.2.067 Long-term effects of aripiprazole on affective symptoms of schizophrenia
2004 ·European Neuropsychopharmacology ·(unknown), Elyse Stock, Д. Арчибалд, Stavros Tourkodimitris, M. Kujawa, R. Marcus, William H. Carson, (unknown)
9
19
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials
2003 ·Schizophrenia Research ·Stephen R. Marder, Robert D. McQuade, Elyse Stock, Stephen Kaplita, Ronald N. Marcus, Allan Z. Safferman, Anutosh Ranjan Saha, Mirza W. Ali, Taro Iwamoto
374
20
Safety and tolerability of aripiprazole in patients with schizophrenia stratified by race
2003 ·Schizophrenia Research ·(unknown), William H. Carson, Elyse Stock, R. Marcus, Д. Арчибалд
2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Virginia L. Stauffer Breakdown of academic impact, for papers by J. Craig Nelson Breakdown of academic impact, for papers by Holland C. Detke Breakdown of academic impact, for papers by Paul Yeung Breakdown of academic impact, for papers by Ronald N. Marcus Breakdown of academic impact, for papers by James M. Martinez Breakdown of academic impact, for papers by Sameer Jauhar Breakdown of academic impact, for papers by Kenneth W. Sommerville Breakdown of academic impact, for papers by Martina Hummer Breakdown of academic impact, for papers by Chiao‐Chicy Chen
Rankless by CCL
2026